Patents by Inventor Scot Wolfe
Scot Wolfe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240141359Abstract: The present invention is related to the field of genetic engineering. In particular, the repair, reversion and/or conversion of genetic mutations that are linked to a muscular dystrophy disease. Specifically contemplated are gene editor nuclease proteins or base editor proteins that are targeted to the muscular dystrophy genetic mutations or pathogenic variants. Such gene editor nuclease proteins include, but are not limited to Cas12a nuclease proteins and adenine base editor proteins. Repair, reversion and/or disruption of the genetic mutation or pathogenic variant reduces at least one symptom of a muscular dystrophy disease.Type: ApplicationFiled: February 23, 2022Publication date: May 2, 2024Inventors: Charles P. Emerson, JR., Scot A. Wolfe
-
Publication number: 20230374476Abstract: The present applications discloses an NLS-optimized SpCas9-based prime editor that improves genome editing efficiency exemplified by endogenous loci in cultured cell lines. Using this genome modification system, tumor formation can be initiated through somatic cell editing in the adult mouse. Furthermore, a dual adeno-associated vims (AAVs) is utilized for the delivery of a split-intein prime editor for correction of in vivo pathogenic mutations.Type: ApplicationFiled: February 4, 2022Publication date: November 23, 2023Inventors: Shun-Qing Liang, Pengpeng Liu, Wen Xue, Scot Wolfe
-
Publication number: 20230279405Abstract: In some aspects, the disclosure relates to recombinant adeno-associated viruses (rAAVs) comprising a nucleic acid encoding a fusion protein comprising a DNA-binding domain and a transcriptional regulator domain and methods of using the same. In some embodiments, expression of the fusion protein results in modified expression of a target gene in a cell.Type: ApplicationFiled: July 23, 2021Publication date: September 7, 2023Applicant: University of MassachusettsInventors: Miguel Sena Esteves, Scot A. Wolfe
-
Publication number: 20230049455Abstract: RNA-guided programmable cytosine and adenine base editors are a powerful class of genome editing tool for the introduction of localized base transitions without generating a double-stranded DNA break. Base editors (BE) have an optimal window of activity relative to the PAM recognized by the Cas9 enzyme and these constructs are strand selective. Here we demonstrate that fusion of a programmable DNA-binding domain (pDBD) or another Cas9 orthologue to spCas9-BE, we can produce an RNA-programmable Cas9-BE-pDBD chimera or Cas9-BE-Cas9 chimeras with dramatically improved activities and increased targeting range. Cas9-pDBD or Cas9-Cas9 fusion base editors display an expanded targeting repertoire and achieve highly specific genome editing, which can be tailored to achieve extremely precise genome editing at nearly any genomic locus.Type: ApplicationFiled: January 29, 2021Publication date: February 16, 2023Inventors: Scot A. Wolfe, Pengpeng Liu, Kevin Luk
-
Publication number: 20220290113Abstract: The present invention is related to the field of gene editing. In particular, the gene editing is directed toward single nucleotide base editing. For example, such single nucleotide base editing results in a conversion of a OG base pair to a T*A base pair. The high accuracy and precision of the presently disclosed single nucleotide base gene editor is accomplished by an NmeCas9 nuclease that is fused to a nucleotide deaminase protein. The compact nature of the NmeCas9 coupled with a larger number of compatible protospacer adjacent motifs provide the Cas9 fusion constructs contemplated herein to have a gene editing window that can edit sites that are not targetable by other conventional SpyCas9 base editor platforms.Type: ApplicationFiled: October 15, 2019Publication date: September 15, 2022Inventors: Erik J. Sontheimer, Xin Gao, Aamir Mir, Alireza Edraki, Scot A. Wolfe, Pengpeng Liu
-
Publication number: 20220185862Abstract: In some aspects, the disclosure relates to recombinant adeno-associated viruses (rAAVs) comprising a nucleic acid encoding a fusion protein comprising a DNA-binding domain and a transcriptional regulator domain and methods of using the same. In some embodiments, expression of the fusion protein results in modified expression of a target gene in a cell.Type: ApplicationFiled: February 24, 2020Publication date: June 16, 2022Applicant: University of MassachusettsInventors: Miguel Sena Esteves, Scot A. Wolfe
-
Publication number: 20220186218Abstract: Provided herein are ribonucleoprotein (RNP) complexes comprising a DNA-targeting endonuclease Cas (CRISPR-associated) protein and a guide RNA (gRNA) that that targets and hybridizes to the ?-Globin gene. In one embodiment, the Cas protein is Cas9 and the gRNA comprises the sequence of SEQ ID NO: 1. In one embodiment, the Cas protein is Cas12a and the gRNA comprises the sequence of SEQ ID NO: 3.Type: ApplicationFiled: January 24, 2020Publication date: June 16, 2022Applicants: THE CHILDREN'S MEDICAL CENTER CORPORATION, UNIVERSITY OF MASSACHUSETTSInventors: Daniel E. BAUER, Shuqian XU, Scot A. WOLFE, Kevin LUK
-
Publication number: 20220017865Abstract: Provided herein are reagents and methods for targeting the ELANE gene for inhibition. Further provided herein is a method for producing a progenitor cell or a population of progenitor cells having decreased ELANE mRNA or protein expression.Type: ApplicationFiled: November 27, 2019Publication date: January 20, 2022Applicants: THE CHILDREN'S MEDICAL CENTER CORPORATION, UNIVERSITY OF MASSACHUSETTSInventors: Josias Brito FRAZĂO, Scot A. WOLFE, Daniel E. BAUER, Shuquan RAO, Peter E. NEWBURGER
-
Publication number: 20210395710Abstract: The present invention provides a Cas9 platform to facilitate single-site nuclease gene editing precision within a human genome. For example, a Cas9 nuclease/DNA-targeting unit (Cas9-DTU) fusion protein precisely delivers a Cas9/sgRNA complex to a specific target site within the genome for subsequent sgRNA-dependent cleavage of an adjacent target sequence. Alternatively, attenuating Cas9 binding using mutations to the a protospacer adjacent motif (PAM) recognition domain makes Cas9 target site recognition dependent on the associated DTU, all while retaining Cas9's sgRNA-mediated DNA cleavage fidelity. Cas9-DTU fusion proteins have improved target site binding precision, greater nuclease activity, and a broader sequence targeting range than standard Cas9 systems. Existing Cas9 or sgRNA variants (e.g., truncated sgRNAs (tru-gRNAs), nickases and FokI fusions) are compatible with these improvements to further reduce off-target cleavage.Type: ApplicationFiled: May 6, 2021Publication date: December 23, 2021Inventors: Scot A Wolfe, Mehmet Fatih Bolukbasi, Ankit Gupta, Erik J. Sontheimer, Nadia Amrani
-
Publication number: 20210388348Abstract: Chemically modified crRNAs and tracrRNAs are provided. crRNAs and tracrRNAs with 5? and/or 3? conjugated moieties are provided. crRNAs and tracrRNAs with modifications in the repeat region of the crRNA or the anti-repeat region of the tracrRNA are provided. Methods of using the crRNAs and tracrRNAs for genome editing with a CRISPR nuclease and kits for performing the same are also provided.Type: ApplicationFiled: May 12, 2021Publication date: December 16, 2021Inventors: Erik Joseph Sontheimer, Anastasia Khvorova, Jonathan Kenneth Watts, Nadia Amrani, Zexiang Chen, Matthew Hassler, Dimas Echeverria Moreno, Julia Frances Alterman, Scot Wolfe, Ken Yamada, Gitali Devi, Han Zhang
-
Publication number: 20210230568Abstract: The present invention is directed to the filed of gene therapy. In particular, compositions and methods are disclosed that repair gene microduplication mutations by reversion to a wild type sequence. For example, the creation of a double stranded break by a programmable nuclease protein within a microduplication induces the microhomology mediated end joining DNA repair pathway that in the process of DNA repair removes the microduplication mutation and restores the wild type sequence.Type: ApplicationFiled: May 3, 2019Publication date: July 29, 2021Inventors: Scot A. Wolfe, Charles P. Emerson, JR., Sukanya Iyer, Sneha Suresh, Christian Mueller, Jennifer Chen, Dongsheng Guo, Oliver King
-
Publication number: 20210115420Abstract: Provided herein are synthetic nucleic acids that encode a CRISPR enzyme fused to a series of nuclear localization signal sequences for the use of altering expression of a gene in a cell. Further provided herein are methods for altering gene expression in a cell comprising introducing the synthetic nucleic acids and a guide RNA, or a polypeptide and a guide RNA into a cell. In certain embodiments the cell is a quiescent cell, for example, a hematopoietic stem cell.Type: ApplicationFiled: May 1, 2019Publication date: April 22, 2021Applicants: THE CHILDREN'S MEDICAL CENTER CORPORATION, UNIVERSITY OF MASSACHUSETTSInventors: Daniel E. BAUER, Scot A. WOLFE, PengPeng LIU, Yuxuan WU, Jing ZENG
-
TARGETING BCL11A DISTAL REGULATORY ELEMENTS WITH A CAS9-CAS9 FUSION FOR FETAL HEMOGLOBIN REINDUCTION
Publication number: 20210047632Abstract: Provided herein are methods and compositions for increasing fetal hemoglobin levels in a cell by disrupting BCL11A expression at the genomic level. Also provided herein are methods and compositions relating to the treatment of hemoglobinopathies by reinduction of fetal hemoglobin levels.Type: ApplicationFiled: July 20, 2018Publication date: February 18, 2021Applicants: THE CHILDREN'S MEDICAL CENTER CORPORATION, UNIVERSITY OF MASSACHUSETTSInventors: Daniel E. BAUER, Scot WOLFE, Mehmet Fatih BOLUKBASI, Benjamin ROSCOE, Pengpeng LIU, Kevin LUK, Yuxuan WU, Jing ZENG -
Publication number: 20190276810Abstract: The present invention provides a Cas9 platform to facilitate single-site nuclease gene editing precision within a human genome. For example, a Cas9 nuclease/DNA-targeting unit (Cas9-DTU) fusion protein precisely delivers a Cas9/sgRNA complex to a specific target site within the genome for subsequent sgRNA-dependent cleavage of an adjacent target sequence. Alternatively, attenuating Cas9 binding using mutations to the a protospacer adjacent motif (PAM) recognition domain makes Cas9 target site recognition dependent on the associated DTU, all while retaining Cas9's sgRNA-mediated DNA cleavage fidelity. Cas9-DTU fusion proteins have improved target site binding precision, greater nuclease activity, and a broader sequence targeting range than standard Cas9 systems. Existing Cas9 or sgRNA variants (e.g., truncated sgRNAs (tru-gRNAs), nickases and FokI fusions) are compatible with these improvements to further reduce off-target cleavage.Type: ApplicationFiled: December 19, 2018Publication date: September 12, 2019Inventors: Scot A. Wolfe, Mehmet Fatih Bolukbasi, Ankit Gupta, Erik J. Sontheimer, Nadia Amrani
-
Publication number: 20060288437Abstract: The invention is based on the discovery that one can create a drug-regulated gene regulation system by creating a fusion polypeptide or chimera that includes three portions: a zinc finger (ZF) protein that recognizes and binds to a nucleic acid recognition sequence in the vicinity of a promoter of the target gene, (ii) a dimerization domain of a tetracycline repressor, which contains a drug-dependent switch, and (iii) an accessory domain to alter the expression of the target gene (such as an activation or repression domain). This chimera is administered to, or expressed in, a cell harboring the target gene to be regulated.Type: ApplicationFiled: August 18, 2006Publication date: December 21, 2006Inventor: Scot Wolfe
-
Publication number: 20050287550Abstract: The present application relates to the hybrid selection methods in prokaryotes using counterselectable reporter genes.Type: ApplicationFiled: February 2, 2005Publication date: December 29, 2005Inventors: Scot Wolfe, Xiangdong Meng, Jay Joung
-
Publication number: 20050042732Abstract: The invention is based on the discovery that one can create a drug-regulated gene regulation system by creating a fusion polypeptide or chimera that includes three portions: a zinc finger (ZF) protein that recognizes and binds to a nucleic acid recognition sequence in the vicinity of a promoter of the target gene, (ii) a dimerization domain of a tetrac repressor, which contains a drug-dependent switch, and (iii) an accessory domain to alter the expression of the target gene (such as an activation or repression domain). This chimera is administered to, or expressed in, a cell harboring the target gene to be regulated.Type: ApplicationFiled: December 9, 2002Publication date: February 24, 2005Inventor: Scot Wolfe